Floatz Rating
BB66/100
Confidence
Indicative
Sponsor
Ralph H. Johnson VA Medical Center
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
61High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05669170CT.gov Methylphenidate for Apathy in Veterans With Parkinson's Disease | — | Not Yet Recruiting | — | — | — |
NCT02879136CT.gov TAME-PD - Physical Therapy, Atomoxetine and, Methylphenidate, to Enhance Gait and Balance in Parkinson's Disease | — | Completed | — | — | — |
NCT01244269CT.gov The Effect of Methylphenidate on Non-motor Symptoms and Postural Control in Parkinson's Disease. | — | Terminated | — | — | — |
NCT00914095CT.gov Study of Methylphenidate to Treat Gait Disorders And Attention Deficit In Parkinson's Disease (PARKGAIT-II) | — | Completed | — | — | — |
NCT00526630CT.gov Methylphenidate for the Treatment of Gait Impairment in Parkinson's Disease | — | Completed | — | — | — |
NCT00393562CT.gov Comparison of Modafinil and Methylphenidate in Treatment of Excessive Daytime Sleepiness in Patients With Parkinson's Disease | — | Withdrawn | — | — | — |
NCT00359723CT.gov Methylphenidate and Parkinson's Disease | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Parkinson Disease
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Methylphenidate (this asset) | Ralph H. Johnson VA Medical Center | Approved | BB · 66 |
| Safinamide | Zambon SpA | P4 | A |
| Cvt-301 | Acorda Therapeutics | P3 | A |
| Istradefylline | Georgetown University | P4 | BBB |
| Rasagiline | Guangzhou Henovcom Bioscience Co. Ltd. | P4 | BBB |
| Pardoprunox | Abbott Products | P3 | BBB |
| Opicapone | Bial - Portela C S.A. | P4 | BBB |
| Ropinirole | Titan Pharmaceuticals | P4 | BBB |
| Carbidopa | Tanta University | P4 | BBB |
+42 more in the Parkinson Disease cohort
Other indications for Methylphenidate
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Attention Deficit-Hyperactivity Disorder | — | P4 | BBB · 76 |
| Multiple Sclerosis | — | P3 | BB · 70 |
| Alzheimer Disease | — | P4 | BB · 68 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Methylphenidate in Parkinson Disease. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/methylphenidate-parkinson-disease
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →